This white paper examines how multinational pharmaceutical companies can use second brands to expand medicine access in price-sensitive Asia-Pacific markets while protecting premium-brand pricing. In countries such as Malaysia, India, Thailand, Vietnam, and the Philippines, affordability, limited reimbursement, fragmented insurance, and high out-of-pocket costs often restrict patient access despite strong clinical acceptance. Second brands can support public-sector inclusion, geographic expansion, and wider uptake, but lower pricing alone does not guarantee success. Outcomes also depend on product selection, launch timing, positioning, partnerships, formulary strategy, evidence generation, demand activation, and organizational alignment. The paper provides a practical framework for determi

Join for free to read